News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NeoGenomics, Inc. (NGNM.OB) Expands Next Generation Sequencing Services And Offers 23 Different Profiles For Various Hematologic And Solid Cancers


7/11/2014 9:11:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FT. MYERS, Fla., July 11, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today it has launched 23 new and innovative NeoTYPE Cancer Profiles based on next-generation sequencing (NGS). These new advanced cancer-profiling tools offer oncologists and pathologists a more targeted and comprehensive ability to tailor cancer testing to an individual patient's needs than has ever been available before.

Next-generation sequencing is an advanced molecular testing approach that is used to more precisely detect a variety of mutations using smaller amounts of tissue. As a result, NeoGenomics will accept fine needle aspirate and other minute samples for testing.

In March, NeoGenomics announced that it was the first to offer plasma-based Next-generation tests for hematologic neoplasms. This testing can allow patients to avoid a bone marrow biopsy, and allow clinicians to monitor tumor load and detect emerging subclones. NeoTYPE plasma-based testing using NGS is now available for AML Prognostic, CLL Prognostic, JMML, Lymphoma, MDS/CMML, MPN, and a comprehensive, 54-gene Myeloid Disorders Profile.

Similarly, the NeoTYPE solid tumor tests are designed to provide precise and complete coverage of "actionable" molecular abnormalities found specifically in the tested tumor. NeoTYPE solid tumor cancer testing is available for Brain, Breast, Cervix, Colorectal, Endometrial, Esophageal, Gastrointestinal Stromal (GIST), Lung, Melanoma, Ovarian, Soft Tissue, Thyroid, and Other Solid Tumors.

Douglas VanOort, the company's Chairman and CEO, said "Tumor profiling is the key to precision medicine, and we are eager to put next-generation sequencing tools into the hands of our physician clients. We have worked hard to develop an innovative and unique approach, using multiple technologies, plasma testing, expert result interpretation and reporting, and other tools to make cancer testing efficient for our health care system and informative for physicians and patients. Our company considers it a privilege to provide the most advanced tools available for the very personalized treatment of a patient's cancer."

Dr. Maher Albitar, the Company's Chief Medical Officer and Director of Research and Development, commented, "These new profiles are designed to provide information that clinicians can utilize in the management of their patients. They provide information on clinical behavior, prognosis, and potential response to currently approved drugs and investigational therapies undergoing clinical trials. While each profile covers, on average, less than 20 different actionable molecular abnormalities, physicians can customize each profile and add additional genes from a list of validated genes. We believe that these small targeted profiles of driver genes are the most clinically justifiable approach to cancer testing given the targeted drugs that are currently available."

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIAcertified clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Fresno, CA, Sacramento, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

SOURCE NeoGenomics, Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES